Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: flickerful who wrote (451)	1/21/1998 9:07:00 AM
From: 5,17,37,5,101,...	Respond to of 756

I am expecting earnings release surprise to the upside in mid Feb. (though I don't know by how much: consensus is -$0.34, max is -$0.25.) A release near the max would give us good support and likely cause some shorts to cover. And I am expecting drug approval releases very soon. And I am expecting an asset sale or two. Oh Froooost, (whistle), here boy, Frooooost!, go get 'em boy! Jackson

To: flickerful who wrote (451)	1/21/1998 9:29:00 AM
From: 5,17,37,5,101,...	Read Replies (1) \| Respond to of 756

The Heard on the Street column in the WSJ briefly refers to "looming drug patent expirations" as a cause for consolidation in the drug industry. That article "Drug Deluge" in the Financial Times said much the same as have other sources. This is counter to the 10/1/97 Oppenheimer report which stated that fewer drugs as measured by dollar sales will go off patent in 1998/9 compared to 1997. I'm inclined to discount the Oppenheimer report as too pessimistic (Michael Metz has been bearish since about 1993/4). But to be wrong on point of fact is a little strange. Jackson